Publications dans lesquelles il/elle collabore avec José Luis Molinuevo Guix (31)

2022

  1. Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease

    Molecular neurodegeneration, Vol. 17, Núm. 1, pp. 27

  2. Correction: Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease (Molecular Neurodegeneration, (2022), 17, 1, (27), 10.1186/s13024-022-00521-3)

    Molecular Neurodegeneration

2021

  1. Accelerated long-term forgetting in individuals with subjective cognitive decline and amyloid-β positivity

    International Journal of Geriatric Psychiatry, Vol. 36, Núm. 7, pp. 1037-1049

  2. Csf proteomic alzheimer’s disease-predictive subtypes in cognitively intact amyloid negative individuals

    Proteomes, Vol. 9, Núm. 3

  3. Long runs of homozygosity are associated with Alzheimer’s disease

    Translational Psychiatry, Vol. 11, Núm. 1

  4. Replication study of plasma proteins relating to Alzheimer's pathology

    Alzheimer's and Dementia, Vol. 17, Núm. 9, pp. 1452-1464

  5. Sex-specific metabolic pathways were associated with alzheimer’s disease (Ad) endophenotypes in the european medical information framework for ad multimodal biomarker discovery cohort

    Biomedicines, Vol. 9, Núm. 11

2020

  1. Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology

    Journal of Alzheimer's Disease, Vol. 77, Núm. 3, pp. 1353-1368

  2. Genome-wide association study of Alzheimer’s disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset

    Translational Psychiatry, Vol. 10, Núm. 1

  3. Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics

    Brain, Vol. 143, Núm. 12, pp. 3776-3792

  4. Validation of plasma proteomic biomarkers relating to brain amyloid burden in the EMIF-Alzheimer's disease multimodal biomarker discovery cohort

    Journal of Alzheimer's Disease, Vol. 74, Núm. 1, pp. 213-225

  5. World-Wide FINGERS Network: A global approach to risk reduction and prevention of dementia

    Alzheimer's and Dementia, Vol. 16, Núm. 7, pp. 1078-1094

2019

  1. A metabolite-based machine learning approach to diagnose Alzheimer-type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort

    Alzheimer's and Dementia: Translational Research and Clinical Interventions, Vol. 5, pp. 933-938

  2. Changes in synaptic proteins precede neurodegeneration markers in preclinical Alzheimer’s disease cerebrospinal fluid*

    Molecular and Cellular Proteomics, Vol. 18, Núm. 3, pp. 546-560

  3. Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay

    Alzheimer's and Dementia, Vol. 15, Núm. 11, pp. 1478-1488

  4. Early detection of subtle motor dysfunction in cognitively normal subjects with amyloid-β positivity

    Cortex, Vol. 121, pp. 117-124

  5. Genome-wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks: The GR@ACE project

    Alzheimer's and Dementia, Vol. 15, Núm. 10, pp. 1333-1347

  6. Inflammatory biomarkers in Alzheimer's disease plasma

    Alzheimer's and Dementia, Vol. 15, Núm. 6, pp. 776-787

  7. Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study

    Alzheimer's and Dementia, Vol. 15, Núm. 6, pp. 742-753

  8. Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort

    Alzheimer's and Dementia, Vol. 15, Núm. 6, pp. 817-827